App-Quantinova.ai

Emerging parkinsonism in the PREDICT-PD cohort after 6-years of follow-up

C. Simonet - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Evaluating a Novel Home-Based Care Pathway for People with Parkinson’s Disease

E. King - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Evaluation of bedside tests of attention in delirium superimposed on Parkinson’s disease and dementia

R. Lawson - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Lewy body dementia

N/A

Exercise habits of People with Parkinson’s across different ethnic populations

A. Podlewska - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Experiences of home-based dance participation in people with Parkinson’s

J. Bek - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Exploring the usefulness of Repetitive Transcranial Magnetic Stimulation for treatment of pain and fatigue in Parkinson’s disease

A. Latorre - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Fine-grained prediction of Huntington’s disease stage using a meta-model approach

M. Kohli - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Huntington's disease

N/A

GBA Mutation Accumulates Higher Alpha-Synuclein in Alpha-Synucleinopathies

T. Eid - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Velaglucerase alfa

Global access to Parkinson’s disease treatment

JLY. Cheong - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Carbidopa and Levodopa

GP2: training the next generation of Parkinson’s disease genetics researchers – wherever they are in the world

S. Dey - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

HbA1c correlates with motor and cognitive outcome scores in patients with Parkinson’s disease and type 2 diabetes.

B. Huxford - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Parkinson's disease

N/A

Identifying and Controlling Variability in Digital Health Measures in Parkinson’s disease Clinical Trials

G. Roussos - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

iFall: Co-producing an instrumented application prototype for falls reporting in Parkinson’s disease

R. Morris - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Impact of 3-month earlier versus postponed initiation of opicapone versus entacapone in levodopa-treated patients with Parkinson’s disease and motor fluctuations

C. Carroll - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

entacapone

IMPACT OF STANDARD-OF-CARE MEDICATIONS ON TIME-OFF READOUTS IN CLINICAL TRIALS. A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH

R. Rose - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Levodopa

Impulse control disorders in idiopathic REM sleep behaviour disorder and drug-naive Parkinson’s disease

A. Otaiku - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Dopamine hydrochloride

In vivo relationship between synaptic density and functional connectivity in progressive supranuclear palsy: a multimodal [11C]UCB-J PET and resting state fMRI study.

N. Holland - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Progressive supranuclear palsy

N/A

Influence of demographic characteristics on the effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations: findings from the real-world OPTIPARK study

B. Mohamed - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Informing the design of disease modifying trials for Parkinson’s disease – A Delphi study

M. Zeissler - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Is there a place for virtual support groups for Parkinson’s disease in Africa? Lessons from the Covid-19 pandemic

N. Fothergill-Misbah - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Parkinson's disease

N/A

Filters

45280 Abstracts